NCT05461430 (TraveraRTGx) is a clinical trial in Pleural Effusion, Malignant, sponsored by Travera Inc.

Who is sponsoring NCT05461430?

NCT05461430 is sponsored by Travera Inc.

What condition does NCT05461430 study?

NCT05461430 studies Pleural Effusion, Malignant, Ascites, Malignant, Carcinoma, Carcinoma, Hepatocellular, Carcinoma, Renal Cell, Carcinoma, Renal, Carcinoma, Small Cell, Carcinoma, Non-Small-Cell Lung, Carcinoma, Pancreatic Ductal, Carcinoma, Neuroendocrine, Carcinoma, Thymic, Carcinoma, Pancreatic, Carcinoma Breast, Carcinoma, Ovarian, Carcinoma Bladder, Carcinoma of Unknown Primary, Carcinoma of the Head and Neck, Carcinoma of the Oropharynx, Carcinoma of the Larynx, Carcinoma of the Bladder, Carcinoma of Esophagus, Carcinoma of the Nasopharynx, Carcinoma of the Penis, Carcinoma of the Cervix, Carcinoma of the Anus, Carcinoma of the Vulva, Carcinoma of the Appendix, Carcinoma of the Oral Cavity, Cholangiocarcinoma, Melanoma, Mesothelioma, Pancreatic Cancer.

Is NCT05461430 still recruiting?

NCT05461430 is currently completed. Last updated 13 April 2026.

Last reviewed 2026-04-13 · How we verify

NCT05461430: TraveraRTGx

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Mass Response of Tumor Cells as a Biomarker for Rapid Therapy Guidance (TraveraRTGx)

Completed Last updated 13 April 2026

What this trial tests

trial in Pleural Effusion, Malignant in 72 participants. Completed in 23 March 2026.

Timeline

15 July 2022

Primary endpoint
23 March 2026

23 March 2026

Quick facts

Lead sponsor	Travera Inc
Status	Completed
Study type	OBSERVATIONAL
Enrollment	72
Start date	15 July 2022
Primary completion	23 March 2026
Estimated completion	23 March 2026
Sites	1 location across United States

Conditions studied

Pleural Effusion, Malignant — all drugs for Pleural Effusion, Malignant →
Ascites, Malignant — all drugs for Ascites, Malignant →
Carcinoma — all drugs for Carcinoma →
Carcinoma, Hepatocellular — all drugs for Carcinoma, Hepatocellular →

Sponsor

Travera Inc — full company profile →

Who can join

18 and older, any sex, with Pleural Effusion, Malignant or Ascites, Malignant. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The primary objective of this study, sponsored by Travera Inc. in Massachusetts, is to validate whether the mass response biomarker has potential to predict response of patients to specific therapies or therapeutic combinations using isolated tumor cells from various specimen formats including malignant fluids such as pleural effusions and ascites, core needle biopsies, fine needle aspirates, or resections.

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

Liquid biopsy into the clinics: Current evidence and future perspectives.
Boukovala M, Westphalen CB, Probst V. · · 2024 · cited 29× · PMID 40027149 · DOI 10.1016/j.jlb.2024.100146
Promising and Minimally Invasive Biomarkers: Targeting Melanoma.
Spiliopoulou P, Holanda Lopes CD, Spreafico A. · · 2023 · cited 6× · PMID 38201222 · DOI 10.3390/cells13010019

Verify or expand the search:

Other recruiting trials for Pleural Effusion, Malignant

Currently open trials in the same condition.

NCT06946498 — First Local Anaesthesia Thoracoscopy for Pleural Effusion Diagnosis. · NA · recruiting
NCT06512896 — Clinical Study on Intraluminal Injection of FOLactis · NA · recruiting
NCT05268172 — IFN-γ Combined With T Cells in the Treatment of Refractory Malignant Pleural Effusion and Ascites · Phase 1 · recruiting
NCT04844827 — Pleural Carcinomatosis Tissue Banking · recruiting
NCT04684459 — Dual-targeting HER2 and PD-L1 CAR-T for Solid Tumors · EARLY_PHASE1 · recruiting

Other Travera Inc trials

Trials by the same sponsor.

NCT03777410 — Mass Accumulation Rate (MAR) as a Predictive Biomarker in Multiple Myeloma · terminated

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05461430 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Travera Inc
Last refreshed: 13 April 2026

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05461430.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing